Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Short Interest Up 26.5% in March

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) was the target of a significant growth in short interest in March. As of March 15th, there was short interest totalling 3,250,000 shares, a growth of 26.5% from the February 28th total of 2,570,000 shares. Based on an average trading volume of 926,100 shares, the short-interest ratio is currently 3.5 days. Approximately 3.2% of the company's stock are short sold.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded down $37.19 on Friday, reaching $573.45. 1,547,645 shares of the company's stock traded hands, compared to its average volume of 687,961. The stock has a 50-day simple moving average of $676.70 and a 200-day simple moving average of $779.13. Regeneron Pharmaceuticals has a 12 month low of $572.00 and a 12 month high of $1,211.20. The firm has a market cap of $62.69 billion, a PE ratio of 14.98, a P/E/G ratio of 2.34 and a beta of 0.44. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. During the same period in the previous year, the firm earned $11.86 EPS. The firm's revenue was up 10.3% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Remove Ads

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.61%. Regeneron Pharmaceuticals's dividend payout ratio is 2.30%.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Pinney & Scofield Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $25,000. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $26,000. OFI Invest Asset Management purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $28,000. Rakuten Securities Inc. increased its stake in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 15 shares during the last quarter. Finally, Avalon Trust Co purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $36,000. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on REGN. BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a report on Tuesday, February 4th. Robert W. Baird dropped their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a report on Wednesday, February 5th. Leerink Partnrs raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. JPMorgan Chase & Co. lowered their price target on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a research report on Monday, March 31st. Finally, Citigroup dropped their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $966.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.